Literature DB >> 26987998

Transplacental sildenafil rescues lung abnormalities in the rabbit model of diaphragmatic hernia.

Francesca M Russo1, Jaan Toelen2, M Patrice Eastwood3, Julio Jimenez4, Andre Hadyme Miyague3, Greetje Vande Velde5, Philip DeKoninck3, Uwe Himmelreich6, Patrizia Vergani7, Karel Allegaert8, Jan Deprest9.   

Abstract

INTRODUCTION: The management of congenital diaphragmatic hernia (DH) would benefit from an antenatal medical therapy, which addresses both lung hypoplasia and persistent pulmonary hypertension. We aimed at evaluating the pulmonary effects of sildenafil in the fetal rabbit model for DH.
METHODS: We performed a dose-finding study to achieve therapeutic fetal plasmatic concentrations without toxicity following maternal sildenafil administration. Subsequently, DH fetuses were randomly exposed to transplacental placebo or sildenafil 10 mg/kg/day from gestational day 24 until examination at term (day 30). Efficacy measures were ipsilateral pulmonary vascular and airway morphometry, micro-CT-based branching analysis, Doppler flow in the main pulmonary artery and postnatal lung mechanics.
RESULTS: Fetal sildenafil plasmatic concentration was above the minimal therapeutic level for at least 22 h/day without maternal and fetal side effects. The placebo-exposed DH fetuses had increased wall thickness in peripheral pulmonary vessels and significantly less fifth-order vessels compared with controls (CTR). Sildenafil-exposed DH fetuses, instead, had a medial and adventitial thickness in peripheral pulmonary vessels in the normal range and normal vascular branching. Fetal pulmonary artery Doppler showed a reduction of pulmonary vascular resistances both in DH and in CTR fetuses treated by sildenafil compared with the placebo-treated ones. Sildenafil also reversed the mean terminal bronchiolar density to normal and improved lung mechanics, yet without measurable impact on lung-to-bodyweight ratio.
CONCLUSIONS: In the rabbit model for DH, antenatal sildenafil rescues vascular branching and architecture, reduces pulmonary vascular resistances and also improves airway morphometry and respiratory mechanics. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  Paediatric Lung Disaese; Rare lung diseases

Mesh:

Substances:

Year:  2016        PMID: 26987998     DOI: 10.1136/thoraxjnl-2015-207949

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  11 in total

Review 1.  X-ray-Based 3D Virtual Histology-Adding the Next Dimension to Histological Analysis.

Authors:  J Albers; S Pacilé; M A Markus; M Wiart; G Vande Velde; G Tromba; C Dullin
Journal:  Mol Imaging Biol       Date:  2018-10       Impact factor: 3.488

Review 2.  Prenatal intervention for the management of congenital diaphragmatic hernia.

Authors:  Mariatu A Verla; Candace C Style; Oluyinka O Olutoye
Journal:  Pediatr Surg Int       Date:  2018-04-30       Impact factor: 1.827

Review 3.  Early diagnosis and targeted approaches to pulmonary vascular disease in bronchopulmonary dysplasia.

Authors:  Catheline Hocq; Laetitia Vanhoutte; Axelle Guilloteau; Anna Claudia Massolo; Bénédicte Van Grambezen; Kate Carkeek; Fiammetta Piersigilli; Olivier Danhaive
Journal:  Pediatr Res       Date:  2021-03-05       Impact factor: 3.756

Review 4.  Fetal endoscopic tracheal occlusion for congenital diaphragmatic hernia: a narrative review of the history, current practice, and future directions.

Authors:  Erin E Perrone; Jan A Deprest
Journal:  Transl Pediatr       Date:  2021-05

5.  Antenatal sildenafil administration to prevent pulmonary hypertension in congenital diaphragmatic hernia (SToP-PH): study protocol for a phase I/IIb placenta transfer and safety study.

Authors:  Francesca Maria Russo; Alexandra Benachi; Tim Van Mieghem; Jan De Hoon; Kristel Van Calsteren; Pieter Annaert; Jean-Marc Tréluyer; Karel Allegaert; Jan Deprest
Journal:  Trials       Date:  2018-09-27       Impact factor: 2.279

6.  Intra-amniotic Sildenafil Treatment Modulates Vascular Smooth Muscle Cell Phenotype in the Nitrofen Model of Congenital Diaphragmatic Hernia.

Authors:  Frances C Okolo; Guangfeng Zhang; Julie Rhodes; Douglas A Potoka
Journal:  Sci Rep       Date:  2018-12-05       Impact factor: 4.379

Review 7.  Emerging antenatal therapies for congenital diaphragmatic hernia-induced pulmonary hypertension in preclinical models.

Authors:  Kathleen Marulanda; Nick D Tsihlis; Sean E McLean; Melina R Kibbe
Journal:  Pediatr Res       Date:  2020-10-10       Impact factor: 3.756

Review 8.  The heart in congenital diaphragmatic hernia: Knowns, unknowns, and future priorities.

Authors:  Neil Patel; Anna C Massolo; Ulrike S Kraemer; Florian Kipfmueller
Journal:  Front Pediatr       Date:  2022-08-16       Impact factor: 3.569

9.  Study protocol: a core outcome set for perinatal interventions for congenital diaphragmatic hernia.

Authors:  Simen Vergote; Felix De Bie; Jan Bosteels; Holly Hedrick; James Duffy; Beverley Power; Alexandra Benachi; Paolo De Coppi; Caraciolo Fernandes; Kevin Lally; Irwin Reiss; Jan Deprest
Journal:  Trials       Date:  2021-02-23       Impact factor: 2.279

Review 10.  Congenital diaphragmatic hernias: from genes to mechanisms to therapies.

Authors:  Gabrielle Kardon; Kate G Ackerman; David J McCulley; Yufeng Shen; Julia Wynn; Linshan Shang; Eric Bogenschutz; Xin Sun; Wendy K Chung
Journal:  Dis Model Mech       Date:  2017-08-01       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.